Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Naldemedine for Opioid-induced Constipation in Non-malignant Chronic Pain
2013-002949-11Phase 3Completed
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in opioid-induced constipation (OIC) comparing Naldemedine with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events, Incidence of serious adverse events and 1 more. Started Nov 2013; status: completed.
02
Drugs
naldemedine
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2013-002949-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002949-11.